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Abstract
Background: The urine lipoarabinomannan (LAM) strip-test (DetermineH-TB) can rapidly rule-in TB in HIV-infected persons
with advanced immunosuppression. However, given high rates of empiric treatment amongst hospitalised patients in high-
burden settings (,50%) it is unclear whether LAM can add any value to clinical decision making, or identify a subset of
patients with unfavourable outcomes that would otherwise have been missed by empiric treatment.
Methods: 281 HIV-infected hospitalised patients with suspected TB received urine LAM strip testing, and were categorised
as definite (culture-positive), probable-, or non-TB. Both the proportion and morbidity of TB cases identified by LAM testing,
early empiric treatment (initiated prior to test result availability) and a set of clinical predictors were compared across
groups.
Results: 187/281 patients had either definite- (n = 116) or probable-TB (n = 71). As a rule-in test for definite and probable-TB,
LAM identified a similar proportion of TB cases compared to early empiric treatment (85/187 vs. 93/187, p = 0.4), but
a greater proportion than classified by a set of clinical predictors alone (19/187; p,0.001). Thirty-nine of the 187 (21%) LAM-
positive patients who had either definite- or probable-TB were missed by early empiric treatment, and of these 25/39 (64%)
would also have been missed by smear microscopy. Thus, 25/187 (8%) of definite- or probable-TB patients with otherwise
delayed initiation of TB treatment could be detected by the LAM strip test. LAM-positive patients missed by early empiric
treatment had a lower median CD4 count (p = 0.008), a higher median illness severity score (p = 0.001) and increased urea
levels (p = 0.002) compared to LAM-negative patients given early empiric treatment.
Conclusions: LAM strip testing outperformed TB diagnosis based on clinical criteria but in day-to-day practice identified
a similar proportion of patients compared to early empiric treatment. However, compared to empiric treatment, LAM
identified a different subset of patients with more advanced immunosuppression and greater disease severity.
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Introduction
The early high mortality (.25%) amongst hospitalised TB HIV
co-infected patients in resource-poor settings requires urgent
attention [1,2]. The increased incidence of sputum pauci-bacillary,
and disseminated forms of TB in these patients limits the use of
both traditional and new TB diagnostic tools [3–6]. Empiric TB
treatment, based only on clinical and radiological findings is
common (,50%) amongst hospitalised HIV-infected patients with
advanced immunosuppression; given their high pre-test probabil-
ity of disease and illness severity [7,8]. Formalized World Health
Organisation (WHO) clinical algorithms are available to guide
empiric treatment and, despite modest diagnostic accuracy in
ambulatory patients [9,10], evidence suggests that their use may
reduce mortality amongst hospitalised HIV-infected patients [8].
Although death due to undiagnosed TB is common in hospitalised
HIV-infected patients in Africa [2,8], empiric treatment guidelines
and practices are inconsistent, vary between hospitals, and may
needlessly expose patients to toxic drugs. Thus, there remains
a need for simple bedside tools to help guide the early initiation of
TB treatment, where a microbiological diagnosis may be unavail-
able or delayed.
Urinary lipoarabinomannan (LAM) has more recently been
evaluated for the diagnosis of TB in HIV-infected patients [11,12].
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In hospitalised HIV-infected patients, a urinary LAM ELISA
(Alere, USA) has an overall sensitivity of 59–67%, increasing to as
high as 85% in patients with CD4,50 cells/ml, and an overall
specificity of 80–94% [13–15]. In addition, LAM positivity has
been associated with higher mycobacterial burden, more severe
illness, and a higher mortality [15–17]. As an alternative to the
ELISA-kit, LAM can now be detected by a simple, low-cost
(,US$3.5) point-of-care lateral flow assay that is able to provide
results in 25 min from just 60 ml of urine [11,12]. Initial evaluation
studies have confirmed equivalent performance of the urine LAM
strip test compared to the LAM ELISA assay in different settings
[13,18].
However, is this test really useful in ‘real world’ clinical practice
in high HIV prevalence settings? The real value in any diagnostic
lies in its ability to provide information beyond that deducible
from basic clinical and radiographic data, such that it adds
incremental value to routine clinical practice. Useful tests add
value to clinical decision-making by ruling-in patients not other-
wise routinely identifiable, pinpointing otherwise unrecognizable
patients with the highest risk of morbidity and mortality, or by
reducing unnecessary treatment. In this context, our study
investigated whether point-of-care urine LAM strip testing offered
any value over basic clinical and radiological screening, and
whether testing was redundant in the context of routine ‘real
world’ day-to-day clinical practice where empiric treatment is
commonly used. We therefore evaluated LAM strip test perfor-




A study outline is shown in Figure 1. In total, 335 prospectively
recruited adult in-patients patients from four hospitals (three
district- and one tertiary-level) between July 2009 and December
2010 in Cape Town, South Africa were enrolled. Patients were
referred for study inclusion by emergency-room or clinic doctors if
suspected to have HIV-TB co-infection and needed in-patient
care. All patients provided written informed consent and the
University of Cape Town Faculty of Health Sciences Human
Research Ethics Committee approved the study. Clinical in-
formation collected included: demographics, past history of TB,
co-morbidity, symptoms, vital signs (including weight) and
a modified early warning (MEWS) illness severity score [19].
Blood was taken for HIV, CD4 and renal function testing. A chest
radiograph (CXR) was performed in all patients.
TB Diagnostic Sampling and Testing
Consultant-led hospital-based clinicians not associated with the
study team determined the timing and extent of TB diagnostic
work-up and the commencement of empiric anti-TB treatment.
Routine hospital practice includes the collection, where possible, of
two sputum samples in patients able to expectorate and, if extra-
pulmonary TB is suspected, the collection of 1–2 non-sputum
samples from clinically involved sites (e.g. fine needle aspirate of
lymph node, pleural fluid aspirate/biopsy, ascitic tap, lumbar
puncture, pericardial aspiration etc.). Further details of biological
samples collected for TB culture, stratified by patient TB
diagnostic category, are outlined in table 1. Concentrated
fluorescence smear microscopy was performed on NALC/NaOH
processed sputum/non-sputum samples, and cultures were
performed using the MGIT 960 liquid culture system (BD
Diagnostics, USA).
TB Reference Standard and Case Definitions
The reference standard for definite-TB was liquid culture
positivity for Mycobacterium tuberculosis from at least a single sample.
Given the significant potential for misclassification bias due to
challenges of sampling extra-pulmonary compartments, the
significant proportion of sputum scarce patients, and the limited
performance of a single liquid TB culture in HIV-infected patients
[20], patients were further categorised into the following di-
agnostic groups for analysis (Figure 1):
Definite-TB. At least 1 M. tuberculosis sample positive by
liquid culture (either sputum or non-sputum e.g. pleural fluid,
pericardial fluid etc.).
Probable-TB. Not meeting the criterion for definite-TB but
a clinical-radiological picture highly suggestive of TB. All patients
in this group received and showed a good response to anti-TB
treatment at two-month follow-up. Smear-positive but culture-
negative or contaminated patient samples were included in this
group.
Non-TB. No culture-based evidence of M. tuberculosis and an
alternative diagnosis available. No clinical deterioration on two-
month follow-up and no TB treatment given. Patients culture
positive for non-tuberculosis mycobacteria (NTM) and not re-
ceiving anti-TB treatment were assigned to this group.
Unclassifiable TB. Unable to assign to any of the above-
mentioned diagnostic groups due to death of unknown cause
(without autopsy), on-going but uncharacterised symptoms at
follow-up, or loss-to-follow-up at 2 months.
Early Empiric Treatment Definition
In order to compare the diagnostic performance of the urine
LAM strip testing with routine clinical practice, early empiric
treatment was defined as any patient commencing TB treatment
within 24 hours of hospital admission based only on clinical and/
or radiological findings, and prior to the availability of any smear
or culture results. All early empiric treatment decisions, even if
initial made by junior staff (medical officers and registrars), were
approved by the attending consultant general physician.
Modelling Clinical Predictors Using Multiple Imputation
A univariate analysis was used to determined basic clinical,
laboratory and radiological predictors of definite-TB. A set of
multivariate clinical predictors was generated using stepwise
logistic regression modeling. Multiple imputation by chained
Equations (Royston, P & White, I 2011) was used to impute
missing data prior to model building. The variables included in the
logistic regression modeling included the following (number of
missing data points for each variable that were imputated is
indicated in the brackets): sex (2), age (5), previous TB history (0),
known TB contact (0), current smoker (0), cough $2 weeks (0),
productive cough (0), haemoptysis (0), self-reported weight loss (0),
appetite loss (0), recent fever (0), night sweats (0), fatigue (0),
shortness of breath (0), chest pain (0), abdominal pain (0), nausea/
vomiting (0), diarrhea (0), neurological symptoms (0), measured
weight (39), temperature (7), respiratory rate (7), and Modified
early warning score (MEWS) (144) at enrollment, CXR compat-
ibility with TB (24), and urine dipstick abnormalities (0). Different
data appeared to be missing for different patients in a random
fashion. The continuous variables (weight and temperature) were
dichotomised using receiver operating characteristic (ROC)
analysis to identify cut-points that maximised discriminatory
utility prior to inclusion in the model. Rounded ß-coefficients
from the reduced model of significant variables were used to
generate scores to quantitate relevant clinical predictors. ROC
analysis was performed and three cut-points were selected for rule-
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in, Youden’s index (the optimal mathematical balance between
sensitivity and specificity [21]) and rule-out value. Diagnostic
accuracy, including 95% confidence intervals, for each cut-point
was assessed using sensitivity, specificity, positive and negative
predictive values (PPV, NPV) and positive likelihood ratio (LR+).
Urine Sampling and LAM Methodology
All patients gave a spot urine sample (10–30 ml) collected in
a sterile container as soon as possible after recruitment. Urine was
frozen on the day of collection and stored at 220uC for later
batched testing. Urine LAM strip testing (DetermineH TB, Alere,
USA) was performed on thawed urine according to the
manufacturer’s instructions by readers blinded to all patient data
and reference test results. Urine LAM strip test lot#101102, the
same as used for test evaluation in an outpatient ARV-clinic
setting [18], was used. Detailed methodology for reading the urine
LAM strip tests has been previously described [13]. Analysis was
performed using the grade 2 cut-point which has shown better
inter-observer reliability and good rule-in value (LR+ .10) in
hospitalised HIV-infected patients [13].
Statistical Analysis
Analyses were restricted to HIV infected patients only and were
performed using definite- and probable- (combined) versus non-
TB patient groups for the primary determination of diagnostic
accuracy (unclassifiable patients were excluded). In addition, given
the inability to accurately evaluate the specificity of empiric
treatment in the primary analysis as treatment response formed
part of the diagnostic categorisation, alternative analyses were
performed (see online supplementary material) using either M.
tuberculosis complex culture-positive versus negative groups, or only
definite- versus non-TB groups. Diagnostic accuracy, including
95% confidence intervals, for individual tests and early empiric
treatment was assessed using sensitivity, specificity and LR+.
Given the variations in test specificity and very high study
prevalence of TB, ranges of positive and negative predicative
values are presented for individual tests and early empiric
treatment at differing rates of in-patient TB prevalence. STATA
IC, version 11 (Stata Corp, Texas, USA) was used for all statistical
analyses.
Results
Demographics, Basic Clinical and TB Diagnostic Sampling
Characteristics
Figure 1 outlines the study population. 16% (54/335) of
enrolled patients were HIV uninfected and hence excluded from
further analysis. 41% (116/281) of patients had definite-TB, an
additional 25% (71/281) of patients had probable-TB, and only
10% (27/281) had non-TB. 24% (67/281) of patients remained
unclassifiable due to death or lost-to-follow-up and were excluded
from the primary analysis. Table 1 outlines demographics, basic
clinical characteristics of the patient cohort and the sputum/non-
sputum diagnostic samples stratified by TB diagnostic category.
These same patient characteristics stratified by smear, culture and
CD4 count have been previously described [13,22]. The median
Figure 1. Study population, culture status and diagnostic groups used for analyses.
doi:10.1371/journal.pone.0054875.g001
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(IQR) CD4 cell count of unclassifiable patients was 77 (42–120)
cells/ml, similar to definite-TB patients [86 (42–192) cells/ml], but
lower than either probable- [120 (51–215) cells/ml] or non-TB
patients [128 (74–235) cells/ml] (p = 0.001). Compared to definite-
TB patients, unclassifiable patients provided fewer non-sputum
samples for TB culture [67% (78/116) vs. 42% (28/67), p,0.001].
Routine Early Empiric Treatment Compared to the Urine
LAM Strip Test
Table 2 compares the sensitivity (95% CI), specificity and LR+
of routine early empiric treatment, urine LAM strip test and CXR
for definite- and probable-TB compared to non-TB patients
(definite-TB to non-TB patients only compared in table S2). Early
empiric treatment identified and the urine LAM strip test
diagnosed an approximately equal number TB cases with
sensitivities of 50% (43–57, 93/187) and 46% (39–53, 85/187)
respectively (p = 0.4). The combined sensitivity of urine LAM strip
testing together with early empiric treatment was higher than
either modality alone [LAM and early empiric treatment: 71%
(95% CI: 64–77, 132/187) vs. LAM alone: 46% (95% CI: 39–53,
85/187) vs. early empiric treatment alone: 50% (95% CI: 43–57,
93/187), both p,0.001]. In the primary analysis, both early
empiric treatment and the urine LAM strip test showed
specificities .95%. However, when an alternative analysis re-
stricted to only patients with a valid M. tuberculosis culture result
and comparing culture-positive and -negative groups is performed
(results provided in table S1), although test sensitivities are not
significantly lower, the specificities of both early empiric treatment
and urine LAM strip testing decrease, with urine LAM offering
higher specificity than early empiric treatment [75% (67–82, 95/
126) vs. 63% (54–71, 79/126), p = 0.03]. Given this variable test
specificity and high overall study TB prevalence, Table 3 presents
a range of PPV (95% CI) and NPV values using three specificities
for each diagnostic method (lowest, highest and average) at in-
patient TB prevalence rates of 35%, 45%, and 55%, which could
be expected to occur in the majority of endemic country hospital
settings. The lowest specificities used in Table 3 are taken from the
specificities presented in table S1, the highest from Table 2 and the
third is an average of the highest and lowest. With an in-patient
TB prevalence of 45% (M. tuberculosis culture positive TB
prevalence in study= 48%, 116/242), the PPV ranges for early
empiric treatment, urine LAM strip test and a combination thereof
was 53–100%, 62–90% and 71–94%, respectively.
Clinical Predictors Compared to the Urine LAM Strip Test
The univariate and multivariate associates of definite-TB are
shown in Table S3. Table S4 shows the sensitivity (95%
confidence intervals), specificity, and LR+ for ROC-selected cut-
points, selected for their rule-in, rule-out, or best compromise
between sensitivity and specificity (assuming equal weighting) for
the quantified set of clinical predictors, the urine LAM strip test
and early empiric treatment. At equivalent specificity, clinical
Table 1. Demographic, clinical, sampling and microbiological characteristics of study patients stratified by TB diagnostic group.
All Definite TB Probable TB Non TB Unclassified TB P-value
N=281 N=116 N=71 N=27 N=67
Demographics
Median age (yrs, IQR) 35 (29–39) 35 (28–39) 33 (30–39) 34 (32–40) 36 (30–41) n/s
Female 174 (62) 69 (59) 45 (63) 19 (70) 41 (61) n/s
Median CD4 count (cells/ml, IQR) 89 (46–198) 86 (42–192)* 120 (51–215)* 128 (74–235)* 77 (42–120)* *0.001
Previous TB 97 (35) 33 (28)* 22 (31) 11 (41) 31 (46)* *0.01
Current Smoker 52 (19) 25 (22) 9 (13) 3 (11) 15 (22) n/s
Clinical features
Cough .2wks 231 (82) 99 (85) 58 (82) 22 (82) 52 (78) n/s
Night sweats 185 (66) 82 (71) 49 (69) 14 (52) 40 (60) n/s
Weight loss 247 (88) 105 (91) 61 (86) 22 (82) 59 (88) n/s
Fever .38uC 49 (18) 29 (26)* *1 9 (13)* 3 (12) 8 (12)*1 *0.04
*10.03
CXR compatible with TB 215 (77) 99 (85)* *1 50 (70)* 16 (60)*1 50 (75) *0.01
*10.002
Early Empiric Rx given 120 (43) 59 (51) 34 (48) n/a 27 (40) n/s
LAM strip test positive (grade 2) 98 (35) 58 (50)* 27 (38)*1 1 (4) 12 (18)* *1 *,0.001
*10.009
Clinical samples collected for TB culture
1 sputum sample 207 (74) 95 (82)* 43 (61)* 21 (78) 48 (72) *0.001
$2 sputum samples 92 (33) 42 (26) 16 (23) 9 (33) 25 (37) n/s
1 non-sputum sample 160 (57) 78 (67)* *1 43 (61) 11 (41)* 28 (42)*1 *0.01
*1,0.001
$2 non-sputum sample 56 (20) 26 (22) 14 (20) 3 (11) 13 (19) n/s
No samples 19 (7) 0 (0) 5 (7) 4 (15) 10 (15) n/s
P-values indicate significant differences between patient groups (marked with * and number to indicate comparison group) for different patient characteristics.
n/a: not applicable; n/s: not significant (p.0.05).
doi:10.1371/journal.pone.0054875.t001
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predictors $2.5 had a lower sensitivity than urine LAM strip
testing [10% (95% CI: 7–15, 19/187) vs. 45% (95% CI: 38–53,
85/187), p,0.001].
Clinical Predictors and Early Empiric Treatment
42% (10/24) of patients ‘ruled-in’ by clinical predictors $2.5
and 38% (23/61) patients ‘ruled-out’ by clinical predictors #0.5
were given early empiric treatment by attending hospital
clinicians. Table S5 provides a further comparison of patient
characteristics for patients commencing vs. not commencing early
empiric treatment. No differences in basic demographic, symp-
tomatology or diagnostic sampling was noted between groups
except that a higher proportion of patients given early empiric
treatment had a cough .2 weeks [90% (108/120) vs. 76% (123/
161), p = 0.003]. Patients given vs. not given early empiric
treatment had a lower median MEWS [3 (1–5) vs. 4 (3–5),
p = 0.001] and creatinine level [68 (56–94) vs. 77 (59–107) mmol/l,
p = 0.04].
Urine LAM Strip Test Positive Patients Missed by Early
Empiric Treatment
The Venn diagram in Figure 2 indicates the different but
overlapping patient populations detected by urine LAM strip and
early empiric treatment initiation. 21% (39/187) of definite- and
probable-TB cases were urine LAM strip test positive, but missed
by early empiric treatment. 64% (25/39) of these patients were
either sputum smear-negative or unable to produce sputum.
Table 4 compares the characteristics of definite- and probable-TB
patients detected by either urine LAM alone, early empiric
treatment or missed by both modalities. Patients detected by urine
LAM alone, when compared to those detected by early empiric
treatment alone, had a lower median (IQR) CD4 cell count [73
(31–134) vs. 138 (60–217), p = 0.008], a higher median (IQR)
MEWS [5 (3–6) vs. 3 (1–4), p = 0.001] and an increased urea level
[5.6 (4.0–11.6) vs. 3.7 (3.2–4.6), p = 0.002]. Patients detected by
urine LAM alone, when compared to those missed by both urine
LAM and early empiric treatment, had lower median CD4 cell
count [73 (31–134) vs. 173 (58–269) units, p = 0.003)]. If the
analysis was repeated using only definite-TB patients the findings
were similar (Figure S1) and conclusions unchanged. 24% (28/
116) of culture-positive patients were LAM positive but missed by
early empiric treatment. When compared to the 23% (27/116) of
patients that were LAM-negative but started on early empiric
treatment, they had a lower median (IQR) CD4 cell count [62
(31–110) vs. 107 (54–171) cells/ml, p = 0.05], a higher median
(IQR) MEWS [5 (3–6) vs. 3 (1–4), p = 0.01] and an increased urea
level [5.5 (3.7–11.2) vs. 3.7 (3.4–4.6), p = 0.02]. Patients detected
by urine LAM alone had lower median (IQR) CD4 cell count and
a higher 8-week mortality than those patients missed by both urine
LAM and early empiric treatment [CD4 count: 62 (31–110) vs.
180 (74–308), p = 0.002; 8-week mortality: 24% (6/25) vs. 4% (1/
23), p = 0.05].
Discussion
The point-of-care urine LAM test has potential as a useful
adjunct for rapid TB diagnosis in HIV-infected hospitalised
patients [11,13]. Its added clinical value, however, remains
uncertain given its modest performance characteristics. The key
finding of this study is that LAM detected patients that would have
otherwise been missed by empiric treatment and this subgroup of
patients had more advanced immunosuppression and greater
illness severity. The latter represents a group most likely to benefit
from the initiation of early treatment as they are at high risk.
Traditional and newer TB diagnostics show reduced diagnostic
accuracy in hospitalised co-infected patients, particularly with
advanced immunosuppression, as patients are often unable to
produce sputum for diagnostic testing and/or have disseminated
disease [3]. In addition, these patients present to hospitals with late
stage disease and severe illness [3]. These factors mean that
treatment decisions are commonly made based on clinical and
Table 2. Sensitivity, specificity and positive likelihood ratio of early empiric treatment, the urine LAM strip test, and CXR for TB
diagnosis in hospitalised HIV-infected patients using the definite and probable-TB groups for sensitivity, and the non-TB groups for
specificity analyses.
Diagnostic method Sensitivity (%) (95% CI) Specificity (%) (95% CI) LR+ (95% CI)






























{Any patient commenced on TB treatment within 24 hours of hospital admission based only on clinical and radiological findings, and prior to the availability of any
smear or culture results, is included in this group.







LAM: Lipoarabinomannan; CXR: Chest X-ray; LR+: positive likelihood ratio; 95% CI: 95% Confidence interval; Rx: treatment.
doi:10.1371/journal.pone.0054875.t002
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radiological findings alone, the need for urgent treatment
initiation, and the high background disease prevalence (pre-test
probability). Yet, in this same patient group, clinical and
radiological findings are frequently atypical and/or non-specific,
and this accounts for the poor rule-in value of the set of clinical
predictors that we derived. Indeed, as a ‘rule-in’ test (cut-point
selecting high specificity and PPV) clinical predictors could only
correctly classify ,20% of all patients. This assumes coherent
mathematical analysis of available diagnostic variables. However,
routine clinical decision-making is rather a dynamic Bayesian
process of assimilating an accumulating series of pre-test proba-
bilities [23], and weighting of the overall post-test probability of
disease against a threshold probability for initiating treatment.
Thus, in reality physician practice varies widely and in an attempt
to reduce mortality hospital treatment thresholds are lower than
expected. Indeed, in this study, ,50% of definite- and probable-
TB patients initiated early empiric TB treatment.
Early empiric TB treatment decisions should logically be
targeted to the sickest patients, especially amongst hospitalised
HIV-infected patients with advanced immunosuppression where
given higher mortality rates, treatment-initiation thresholds should
be lowered. However, this was not the case in those empirically
treated. In fact overall, patients not commenced on early empiric
treatment appeared, using the MEWS, to have a higher illness
severity. No clear demographic, clinical or radiological factor
predicted early empiric treatment. By contrast, the urine LAM
strip test could pinpoint the most severely ill patients. Thus, our
data suggest that early empiric treatment will miss a particularly
vulnerable patient group with advanced immunosuppression that
would have been detected by LAM strip testing. The rapid
identification of these patients could target prompt therapy to
those most likely to benefit. Recent studies with both the TB LAM
ELISA and the LAM strip test support our findings, demonstrating
associations between urine LAM positivity, higher mycobacterial
disease burden, more advanced immunosuppression, and in-



















































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Venn diagram of all definite- and probable-TB
patients indicating different but overlapping patient popula-
tions detected by the urine LAM strip test and early empiric TB
treatment.
doi:10.1371/journal.pone.0054875.g002
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support the need to undertake prospective impact studies to assess
whether initiation of TB treatment based on urine LAM testing is
able to save lives and/or decrease TB-related morbidity.
Do our findings have relevance to in-patient settings with a lower
TB prevalence? Amongst in-patient settings with a lower TB
prevalence, urine LAM is likely to offer superior ‘rule-in’ utility
compared to empiric treatment. This is evidenced by: i) the poor
comparative diagnostic utility and inferiority of a set of clinical
predictors, which estimates pre-test probability or what could be
expected with a frequentist interpretation of simple clinical and
radiological predictors, and ii) lack of clear demographic, clinical
or radiological parameters associated with early empiric treatment
practice and limited agreement with the derived set of clinical
predictors indicating the lack of predictability and hence,
standardisation of empiric treatment decision-making. Given the
modest performance characteristics of the urine LAM strip testing
it is however clear that both urine LAM alone, or combined with
existing empiric treatment practise, is likely to only offer clinically
useful ‘rule-in’ utility (PPV.90%) in hospital settings with high TB
prevalence (.35%).
This is the first study to compare the value of urine LAM strip
testing against clinical-radiological screening and day-to-day
clinical practice (early empiric treatment rates) in hospitalised
patients. However, our study has important limitations. Given the
well-established misclassification bias that occurs due to the
drawbacks of the TB culture technique and the lack of
interventional lung sampling (sputum induction and bronchosco-
py), a diagnostic categorisation was used to group patients for
analysis. This may have underestimated sensitivity and over-
estimated specificity. The TB prevalence in our study was higher
than in many other settings and this limits the generalisability of
our findings. However, we have presented predictive values using
estimated low, medium and high TB prevalence rates to improve
generalisability. The study had a high proportion of unclassifiable-
TB patients due to death and loss-to-follow-up, and these patients
had a higher proportion of LAM strip test negative results than
definite- and probable-TB groups. This may have introduced the
possibility of selection bias, however, in our secondary analyses
presented in the online supplementary materials we compare M.
tuberculosis culture positive vs. negative groups and include
unclassifiable-TB patients with a valid culture result. Key study
findings are unaffected. Our study did not evaluate LAM against
newer diagnostic standards such as the Xpert MTB/RIF assay.
However, this was not accessible to us at the time of the study and
this test offers reduced utility in extra-pulmonary and sputum scare
TB. Urine LAM test results were not performed at the bedside or
used to guide treatment initiation, thus a survival benefit through
initiating early treatment in these severely ill patients is unclear but
possible [8].
An ideal point-of-care test for rapid, laboratory-free detection of
TB remains elusive [24]. However sampling hurdles and poor
performance when using extra-pulmonary samples mean that the
need to make empiric treatment decisions is likely to continue.
Thus, despite only modest diagnostic accuracy, the low cost urine
LAM strip test offers important added clinical value in hospitalised
HIV-infected patients with suspected TB. Not only could the test
detect patients missed by clinical and radiological predictors but
also could potentially enable the rapid treatment of patients with
the most advanced immunosuppression and severe illness. Further
studies are now required to confirm our study findings and
evaluate the impact of urine LAM strip testing to guide early
treatment initiation in hospitalised HIV-infected patients.
Supporting Information
Figure S1 Venn diagram of all definite-TB patients indicating
different but overlapping patient populations detected by the urine
LAM strip test and early empiric TB treatment.
(TIFF)
Table S1 Diagnostic accuracy measures of early empiric
treatment, the urine LAM strip test and CXR for TB diagnosis
in hospitalised HIV-infected patients using M. tuberculosis culture
Table 4. Comparison of patient characteristics between groups detected by either the urine LAM strip or early empiric treatment
alone, or missed both bedside diagnostic methods (only patients with definite- or probable-TB were included).
Patient characteristic(s)
LAM strip positive, but no
early empiric Rx given
LAM strip negative, but
early empiric Rx given




Median (IQR) or n(%) Median (IQR) or n(%) Median (IQR) or n(%)
Age, years 32 (26–38) 35 (28–38) 35 (30–40) n/s
Previous TB 12 (31) 16 (34) 18 (33) n/s
Weight, kg 52 (47–60) 56 (44–63) 52 (47–61) n/s
Temperature, uC 36.9 (36.0–37.1) 36.9 (36.5–38.0) 36.9 (36.3–37.7) n/s
Respiratory rate, breaths/min 24 (20–28) 22 (19–29) 24 (18–28) n/s
CD4 cell count, cells/ml 73 (31–134)* # 138 (60–217)* 173 (58–269)# *0.008 #0.003
MEWS1 5 (3–6)* 3 (1–4)* 4 (3–6) *0.001
Urea, mmol/l 5.6 (4.0–11.6)* 3.7 (3.2–4.6)* 4.2 (3.2–7.8) *0.002
Creatinine, mmol/l 95 (59–121)* 67 (55–79)* 74 (57–102) *0.01
8-week mortality 6/36 (17) 3/40 (8) 3/39 (8) n/s
1MEWS: Modified early warning score is an admission triage score based on illness severity and higher scores correlated with poor outcomes and increased mortality
[19].
{P-values indicate significant differences between patient groups (marked with * and # to indicate comparison group) for different patient characteristics.
LAM: Lipoarabinomannan; Rx: treatment; IQR: interquartile range.
doi:10.1371/journal.pone.0054875.t004
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positive-TB patients for sensitivity, and culture negative patients
for specificity analyses. 1All patients with 1 or more valid M.
tuberculosis culture (either sputum or non-sputum) are included in
this analysis irrespective of final TB diagnostic categorization (39/
281 patients excluded with either no/contaminated culture result)
{Any patient commenced on TB treatment within 24 hours of
hospital admission based only on clinical and radiological findings,
and prior to the availability of any smear or culture results, is
included in this group. P-values indicate significant differences
between tests (marked with * and number to indicate comparison
group) for different diagnostic accuracy measures *1p,0.001;
*2p,0.001; *3p,0.001; *4p,0.001; *5p= 0.03; *6p = 0.03;
*7p,0.001; *8p = 0.005.
(DOCX)
Table S2 Diagnostic accuracy measures of early empiric
treatment, the urine LAM strip test and CXR for TB diagnosis
in hospitalized HIV-infected patients using definite-TB (M.
tuberculosis culture positive) for sensitivity, and non-TB patient
groups for specificity analyses. {Any patient commenced on TB
treatment within 24 hours of hospital admission based only on
clinical and radiological findings, and prior to the availability of
any smear or culture results, is included in this group. P-values
indicate significant differences between tests (marked with * and
number to indicate comparison group) for different diagnostic
accuracy measures *1p,0.001; *2p,0.001; *3p,0.001; *4p,0.001;
*5p,0.001.
(DOCX)
Table S3 Univariate and multivariate analyses for associates of
definite-TB in HIV-infected hospitalised patients. {Receiver
operating characteristic (ROC) curve-selected cut-point maximiz-
ing discriminatory utility used to dichotomise the continuous
variables weight and temperature OR: odds ratio; TB: Tubercu-
losis; CXR: Chest x-ray; LAM: Lipoarabinomannan.
(DOCX)
Table S4 Diagnostic accuracy measures for set of clinical
predictors (using three ROC-selected cut-points), the urine LAM
strip test and routine early empiric treatment in hospitalised HIV-
infected patients using the definite and probable-TB groups for
sensitivity and the non-TB groups for specificity analyses. P-values
indicate significant differences between tests and/or cut-points
(marked with * and number to indicate comparison group) for
different diagnostic accuracy measures; *1p,0.001; *2p = 0.03{
Youden’s index is defined as the point on the ROC curve that
provides the optimal mathematical balance between sensitivity and
specificity.
(DOCX)
Table S5 Demographic, clinical, sampling and microbiological
characteristics of study patients stratified by TB diagnostic group {
Any patient commenced on TB treatment within 24 hours of
hospital admission based only on clinical and radiological findings,
and prior to the availability of any smear or culture results, is
included in this group. Analysis is performed for all patients in this
graph and hence includes 27 unclassified patients whom were
commenced on early empiric treatment but do not form part of
the primary analysis presented in the main manuscript. P-values
indicate significant differences between patient groups (marked
with * and number to indicate comparison group) for different
patient characteristics 1MEWS: Modified early warning score is an
admission triage score based on illness severity and higher scores
correlated with poor outcomes and increased mortality [19].
(DOCX)
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